,

. Références,

J. K. Ormond, Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process, J Urol, vol.59, pp.1072-1081, 1948.

A. Vaglio, C. Salvarani, and C. Buzio, Retroperitoneal fibrosis, Lancet, vol.367, pp.241-51, 2006.

A. Khosroshahi, M. N. Carruthers, J. H. Stone, S. Shinagare, N. Sainani et al., Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease, Medicine (Baltimore), vol.92, pp.82-91, 2013.

J. Haroche, F. Cohen-aubart, L. Arnaud, B. Hervier, C. F. Drier et al.,

, Rev Med Interne, vol.35, pp.715-737, 2014.

M. L. Urban, A. Palmisano, M. Nicastro, D. Corradi, C. Buzio et al., Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach, Rev Med Interne, vol.36, pp.15-21, 2015.

P. J. Scheel and N. Feeley, Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation, Medicine (Baltimore), vol.88, pp.202-209, 2009.

E. Van-bommel, I. Jansen, T. R. Hendriksz, and A. Aarnoudse, Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation, Medicine (Baltimore), vol.88, pp.193-201, 2009.

M. Lugosi, K. Sacré, O. Lidove, M. Chauveheid, B. Brihaye et al., Longterm follow-up of a French cohort of retroperitoneal fibrosis, Rev Med Interne, vol.34, pp.591-600, 2013.

E. Van-bommel, L. G. Pelkmans, H. Van-damme, and T. R. Hendriksz, Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis, Eur J Intern Med, vol.24, pp.444-50, 2013.

P. J. Scheel, N. Feeley, and S. M. Sozio, Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series, Ann Intern Med, vol.154, pp.31-37, 2011.

I. Gallais-sérézal, L. Jeune, S. Belenfant, X. Bakir, R. Fain et al., Idiopathic retroperitoneal fibrosis: a multicentric retrospective study of 30 French cases and follow-up of the renal function

, Rev Med Interne, vol.35, pp.570-576, 2014.

M. Goldoni, S. Bonini, M. L. Urban, A. Palmisano, D. Palma et al., Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study, Ann Intern Med, vol.161, pp.181-189, 2014.

A. Vaglio, A. Palmisano, F. Alberici, U. Maggiore, S. Ferretti et al., Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial, Lancet, vol.378, pp.338-384, 2011.

A. H. Kardar, S. Kattan, E. Lindstedt, and K. Hanash, Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration, J Urol, vol.168, pp.550-555, 2002.

M. G. Catanoso, L. Spaggiari, L. Magnani, N. Pipitone, A. Versari et al., Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis, Clin Exp Rheumatol, vol.30, pp.776-784, 2012.

H. Umehara, K. Okazaki, Y. Masaki, M. Kawano, M. Yamamoto et al., A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details, Mod Rheumatol, vol.22, pp.1-14, 2012.

J. H. Stone, A. Khosroshahi, V. Deshpande, J. Chan, J. G. Heathcote et al., Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations, Arthritis Rheum, vol.64, pp.3061-3068, 2012.

Y. Zen, M. Onodera, D. Inoue, A. Kitao, O. Matsui et al., Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4, Am J Surg Pathol, vol.33, pp.1833-1842, 2009.

A. Grados, M. Ebbo, J. E. Bernit, E. Harlé, J. R. Schleinitz et al., Rev Med Interne, vol.36, pp.395-404, 2015.

A. Vaglio, D. Corradi, L. Manenti, S. Ferretti, G. Garini et al., Evidence of autoimmunity in chronic periaortitis: a prospective study, Am J Med, vol.114, pp.454-62, 2003.

G. Ceresini, M. L. Urban, D. Corradi, F. Lauretani, M. Marina et al., Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: a case-control study, Autoimmun Rev, vol.14, pp.16-22, 2015.

N. Voorzanger-rousselot and P. Garnero, Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses, Cancer Treat Rev, vol.33, pp.230-83, 2007.

T. Mirault, M. Lambert, P. Puech, D. Argatu, A. Renaud et al., Malignant retroperitoneal fibrosis: MRI characteristics in 50 patients, Medicine (Baltimore), vol.91, pp.242-50, 2012.

B. Bakir, F. Yilmaz, R. Turkay, S. Ozel, B. Bilgiç et al., Role of diffusionweighted MR imaging in the differentiation of benign retroperitoneal fibrosis from malignant neoplasm: preliminary study, Radiology, vol.272, pp.438-483, 2014.

L. Kamper, A. S. Brandt, H. Ekamp, N. Abanador-kamper, W. Piroth et al., Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis, Diagn Interv Radiol, vol.20, pp.459-63, 2014.

A. B. Rosenkrantz, B. Spieler, C. R. Seuss, M. D. Stifelman, and S. Kim, Utility of MRI features for differentiation of retroperitoneal fibrosis and lymphoma, AJR Am J Roentgenol, vol.199, pp.118-144, 2012.

A. Vaglio, A. Versari, A. Fraternali, F. Ferrozzi, C. Salvarani et al., )F-fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of idiopathic retroperitoneal fibrosis, Arthritis Rheum, vol.53, issue.18, pp.122-127, 2005.

G. Treglia, M. V. Mattoli, F. Bertagna, R. Giubbini, and A. Giordano, Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review, Rheumatol Int, vol.33, pp.549-55, 2013.

I. Jansen, T. R. Hendriksz, S. H. Han, A. Huiskes, and E. Van-bommel, 18)Ffluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis, Eur J Intern Med, vol.21, pp.216-237, 2010.

A. Y. Keehn, P. W. Mufarrij, and M. D. Stifelman, Robotic ureterolysis for relief of ureteral obstruction from retroperitoneal fibrosis, Urology, vol.77, pp.1370-1374, 2011.

A. S. Brandt, L. Kamper, S. Kukuk, P. Haage, and S. Roth, Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry, J Urol, vol.185, pp.526-557, 2011.